Philips completes tender offer for BioTelemetry
Philips acquired BioTelemetry for USD 72.00 per share, making it a wholly owned subsidiary and delisting its stock from NASDAQ.
See the latest news and media coverage for Philips Ambulatory Monitoring and Diagnostics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Connected cardiac monitoring, diagnostic, and care coordination services
gobio.comLast updated
In short: Philips Ambulatory Monitoring and Diagnostics launched a mobile cardiac-monitoring platform to improve alarm management.
Philips acquired BioTelemetry for USD 72.00 per share, making it a wholly owned subsidiary and delisting its stock from NASDAQ.
This strategic acquisition strengthens Philips' remote cardiac diagnostics capabilities and expands its ambulatory monitoring portfolio significantly.
The company achieved a 3% year-over-year growth and net income of $6.7 million while acquiring RPM assets from Centene.
Revenue declined 11.4% due to COVID-19. The company acquired Centene RPM assets and partnered with Boston Scientific and Roche.
Philips launches a new mobile cardiac monitoring platform that improves alarm management...
CAMBRIDGE, Mass. – Royal Philips (NYSE: PHG, AEX: PHIA) a global leader in health technology, today announced a collaboration with Epic to integrate Philips’ suite...
This collaboration will offer the broadest cardiac care portfolio of any single service provider integrating with Aura to date. Philips will deliver a new level...
Philips is integrating its cardiac ambulatory monitoring and diagnostic services within Epic's Aura system. The partnership removes the need for providers and organizations to review...
Track Philips Ambulatory Monitoring and Diagnostics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Philips Ambulatory Monitoring and Diagnostics and other trending companies.